ATOPIX THERAPEUTICS
Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis. Its lead candidate is currently being studied in a Phase 2 clinical trial for moderate to severe atopic dermatitis in several leading European dermatology centres.
ATOPIX THERAPEUTICS
Industry:
Biotechnology Life Science Medical
Founded:
2012-01-01
Address:
Abingdon, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.atopixtherapeutics.co.uk
Total Employee:
1+
Status:
Closed
Contact:
(440) 123-5841
Email Addresses:
[email protected]
Total Funding:
10.46 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF LetsEncrypt SSL By Default Nginx GStatic Google Static Content OVH Cart Functionality
Current Advisors List
Current Employees Featured
Investors List
SV Health Investors
SV Health Investors investment in Venture Round - Atopix Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Atopix Therapeutics
Wellington Partners
Wellington Partners investment in Series A - Atopix Therapeutics
SR One
SR One investment in Series A - Atopix Therapeutics
Bessemer Venture Partners
Bessemer Venture Partners investment in Series A - Atopix Therapeutics
Red Abbey Venture Partners
Red Abbey Venture Partners investment in Series A - Atopix Therapeutics
MPM Capital
MPM Capital investment in Series A - Atopix Therapeutics
Biomedical Catalyst Fund
Biomedical Catalyst Fund investment in Grant - Atopix Therapeutics
Official Site Inspections
http://www.atopixtherapeutics.co.uk
- Host name: 104.247.82.54
- IP address: 104.247.82.54
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Atopix Therapeutics"
Atopix Therapeutics - VentureRadar
Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel …See details»
Chiesi Enhances Asthma Portfolio with Acquisition of …
Parma, Italy — November 21, 2016— Chiesi Farmaceutici Spa (“Chiesi”), announced today that it has signed a definitive agreement for the acquisition of Atopix Therapeutics Limited, a UK clinical stage biotechnology company …See details»
Organization | Atopix Therapeutics, Ltd. - Purdue University
Atopix Therapeutics, Ltd. Report issue. For profit Phase 1 Phase 2. Founded: Oxford United Kingdom (2012 ... Organization Overview. First Clinical Trial. 2013 NCT02002208. First …See details»
Atopix Company Profile 2024: Valuation, Investors, Acquisition
Atopix General Information Description. Developer of novel treatments designed for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-allergic medicines, …See details»
Atopix Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Atopix Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, and 1 literature, Drug:Timapiprant, ATX-2417, ATX-2286.See details»
Atopix Therapeutics - Products, Competitors, Financials, …
About Atopix Therapeutics. Atopix Therapeutics operates as a clinical-stage biotechnology company. The company's main offering includes the development of new molecular entities, …See details»
Atopix Therapeutics Ltd - Company Profile and News
Atopix Therapeutics Ltd. operates as a clinical-stage, biopharmaceutical company. The Company develops anti-inflammatory medicines to treat asthma, chronic allergic conditions, and other …See details»
Atopix Therapeutics acquired by Chiesi Farmaceutici
Atopix Therapeutics is a spinout of a spinout, having been established by Oxagen Limited in 2012. Oxagen itself was first formed using research from Oxford University’s Wellcome Trust …See details»
Atopix Company Profile - Office Locations, Competitors, Revenue …
Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of …See details»
Atopix Therapeutics Secures Funding to Broaden Development of …
Jun 17, 2015 Atopix Therapeutics Ltd Tim Edwards, Executive Chairman +44(0)1235-841563 [email protected] Consilium Strategic Communications Amber Bielecka, Jessica Hodgson, …See details»
Atopix Therapeutics - Contacts, Employees, Board Members
Organization. Atopix Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Highlights. ... Atopix Therapeutics has 2 board members and …See details»
Atopix obtains £1.7m grant to advance ... - Clinical Trials Arena
May 29, 2013 Biopharmaceutical company Atopix Therapeutics has obtained a £1.7m grant from the UK Biomedical Catalyst fund to advance the development of OC459 as a treatment for …See details»
Mick Hunter - Chief Scientific Officer & Director of Development ...
Primary Organization . Atopix Therapeutics . Location Abingdon, Oxfordshire, United Kingdom; Regions Europe, Middle East, and ... and Chief Scientific Officer & Director of Development at …See details»
www.atopixtherapeutics.com Late-stage atopic dermatitis ... - Nature
Atopix Therapeutics Ltd. Abingdon, UK Tel: +44 (0)1235 841522 Email: [email protected] Figure 1: Several compounds are in clinical development …See details»
Atopix Therapeutics awarded Biomedical Catalyst grant to study …
Jun 3, 2013 Atopix Therapeutics Ltd (“Atopix”), a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK …See details»
Chiesi buys Atopix for clinical-stage asthma pipeline
Nov 21, 2016 Chiesi Farmaceutici has bought Atopix Therapeutics for its pipeline of asthma treatments. The buyout gives Chiesi an orally administered CRTh2 antagonist that Atopix is …See details»
Atopix Shows Off Positive Phase 2b Results For Once Daily
Mar 3, 2014 Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma ABINGDON, England--(BUSINESS WIRE)--Atopix Therapeutics Ltd (“Atopix”), a …See details»
Atopix Therapeutics Awarded Biomedical Catalyst Grant
May 30, 2013 Atopix Therapeutics Ltd has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to …See details»
Atopix Recruits First Patient in Phase 2 Trial of OC459 for Atopic ...
Nov 19, 2013 Atopix Therapeutics Ltd has announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic …See details»